Clinical Data Named as One of New England's Fastest Growing Life Sciences Companies by Deloitte
Clinical Data, Inc. has been named for the second year in a row to Deloitte's prestigious Technology Fast 50 Program for New England, a ranking of the 50 fastest growing technology, media, telecommunications and Life Sciences companies in the area by Deloitte & Touche USA LLP, one of the nation's professional services organizations. Rankings are based on the percentage revenue growth over five years from 2001-2005.
Drew Fromkin, President and CEO of Clinical Data, credits the company's acquisition strategy for the company's robust 336 percent revenue growth rate from 2001-2005. Fromkin said, "We are very pleased to be included for two years in a row in the Fast 50 and we are gratified that our business strategy to capitalize on anticipated growth opportunities in pharmacogenomics, pharmacogenetics and related services has begun to deliver the results we anticipated. We believe these initiatives including our focus on Therapeutic Diagnostics(TM), genetic tests that determine how individuals will respond to specific drugs, will assist us in growing the company further in 2006 and beyond. We are proud to be named one of the fastest growing technology companies in New England along with an impressive list of other recipients of this designation."
Clinical Data's increase in revenues of 336 percent from 2001 to 2005 resulted in a 40 ranking in the Technology Fast 50 for New England. The average increase in revenues among companies who made the Technology Fast 50 for this region was 1,825 percent. To qualify for the Technology Fast 50, companies must have had operating revenues of at least $50,000 in 2001 and $5,000,000 in 2005, be headquartered in North America, and be a company that owns proprietary technology or proprietary intellectual property that contributes to a significant portion of the company's operating revenues; or devotes a significant proportion of revenues to the research and development of technology. Using other companies' technology or intellectual property in a unique way does not qualify.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.
